Evidence map›Paper›PMID 21487419›Full record

ReviewNature reviews. Clinical oncology2011

The biology of brain metastases-translation to new therapies.

April F Eichler, Euiheon Chung, David P Kodack, Jay S Loeffler, Dai Fukumura, Rakesh K Jain

Abstract readReview
In one paragraph

Review in Nature reviews. Clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 310 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
310citing papers in PubMed, 9 pooled it
26.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

310 citing papers in PubMed, 9 syntheses or guidelines pooled it, 567 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Brain metastasis: Opportunities for novel therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

250 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

April F EichlerStephen E. and Catherine Pappas Center for Neuro-oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Euiheon Chung
David P Kodack
Jay S Loeffler
Dai Fukumura
Rakesh K Jain
Massachusetts General Hospital · USHarvard University · USCenter for Neuro-Oncology · US

Funding

Vascular Normalization: Rolse of Perivascular CellsP01CA080124 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2000 to 2016
$35.0M
PHASE I TRIALS OF NEW ANTICANCER AGENTSU01CA062490 · NCI · DANA-FARBER CANCER INSTITUTE · PI KUFE, DONALD W. · 1994 to 2013
$10.2M
Integrative Biology of Tumor MetastasisR01CA085140 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2005 to 2009
$8.6M
BIOLOGY OF TUMOR ANGIOGENESIS, INVASION AND METASTASISR24CA085140 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2000 to 2004
$8.3M
Probing Tumor Microenvironment Using NanotechnologyR01CA126642 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2008 to 2012
$8.3M
NO in Tumor Angiogenesis,Microcirculation &Rad.TherapyR01CA096915 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2002 to 2012
$3.0M
Training Program in Pathophysiology of Solid TumorsT32CA073479 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 1998 to 2012
$3.0M
Role of BMDCs in Solid Tumor Growth and RelapseR01CA115767 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2006 to 2010
$2.2M
A phase Ib/II study of AZD2171 and radiation for new brain metastases from NSCLCR21CA135605 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EICHLER, APRIL FITZSIMMONS · 2009 to 2010
$389k
PATHOPHYSIOLOGY OF EXPERIMENTAL AND HUMAN TUMORSR35CA056591 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 1993 to 1999
–
NCI NIH HHS P01 CA080124NCI NIH HHS P01-CA080124NCI NIH HHS R01 CA085140NCI NIH HHS R01-CA085140NCI NIH HHS R01 CA096915NCI NIH HHS R01-CA096915NCI NIH HHS R01 CA115767NCI NIH HHS R01-CA115767NCI NIH HHS R01 CA126642NCI NIH HHS R01-CA126642NCI NIH HHS R21 CA135605NCI NIH HHS R21-CA135605NCI NIH HHS R24 CA085140NCI NIH HHS R35 CA056591NCI NIH HHS T32 CA073479NCI NIH HHS T32-CA073479NCI NIH HHS U01 CA062490NCI NIH HHS U01-CA062490
6 · The paper itself

Abstract

Brain metastases are a serious obstacle in the treatment of patients with solid tumors and contribute to the morbidity and mortality of these cancers. It is speculated that the frequency of brain metastasis is increasing for several reasons, including improved systemic therapy and survival, and detection of metastases in asymptomatic patients. The lack of preclinical models that recapitulate the clinical setting and the exclusion of patients with brain metastases from most clinical trials have slowed progress. Molecular factors contributing to brain metastases are being elucidated, such as genes involved in cell adhesion, extravasation, metabolism, and cellular signaling. Furthermore, the role of the unique brain microenvironment is beginning to be explored. Although the presence and function of the blood-brain barrier in metastatic tumors is still poorly understood, it is likely that some tumor cells are protected from therapeutics by the blood-tumor barrier, creating a sanctuary site. This Review discusses what is known about the biology of brain metastases, what preclinical models are available to study the disease, and which novel therapeutic strategies are being studied in patients.

Indexed as

Blood-Brain BarrierAnimalsBone NeoplasmsDisease Models, AnimalHumansNeoplasms

Identifiers

PMID21487419
PMCPMC3259742
OpenAlexW2355495448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.